IL6 and COVID-19: In another uncontrolled exploratory study in 77 patients with moderate COVID-19, treatment with nebulized IFN-a2b significantly reduced the duration of detectable virus in the upper respiratory tract and in parallel reduced duration of elevated blood levels for the inflammatory markers IL-6 and CRP (44).